Citius Pharmaceuticals- Warrants(02/08/2022) Operating Income

As of the most recent data (June 2026), CTXRW shows a operating income of $-60M. That compares with $-30M in the prior-year period — down 100.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CTXRW's operating income is now $-60M (was $-30M) — a 100.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Citius Pharmaceuticals- Warrants(02/08/2022) is outperforming or lagging.

Tracking CTXRW's operating income over time shows whether Citius Pharmaceuticals- Warrants(02/08/2022) is scaling, shrinking, or reshaping that part of the business. The current reading is $-60M That compares with $-30M in the prior-year period — down 100.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Citius Pharmaceuticals- Warrants(02/08/2022)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-60M) with ownership activity and broader fundamentals.

Citius Pharmaceuticals- Warrants(02/08/2022)'s operating income is $-60M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.